Names and pronunciation
(an-i-FROL-ue-mab-fnia) Saphnelo
PDF page 95
Loading InternPractice…
Drug reference
(an-i-FROL-ue-mab-fnia) Saphnelo
PDF page 95
Func. class.: Monoclonal antibody
PDF page 95
Chem. class.: Type 1 interferon recep- tor antagonist
PDF page 95
ACTION: Binds to subunit 1 of the type I inter- feron, inhibition of type I IFN, blocks plasma cell differentiation and normal- izes peripheral T-cells
PDF page 95
USES: Systemic lupus erythematosus
PDF page 95
CONTRAINDICATIONS Anaphylaxis Precautions: Serious infections, hyper- sensitivity, malignancy, pregnancy, breastfeeding
PDF page 95
SIDE EFFECTS • RESP: Nasopharyngitis, URI, bronchi- tis, cough • INTEG: Infusion-related reactions • SYST: Herpes zoster
PDF page 95
INTERACTIONS Avoid use with other biologic therapies, live, live-attenuated vaccines
PDF page 95
DOSAGE AND ROUTES • Adult: IV INF 300 mg over 30 min q4wk
PDF page 95
Available forms: Injection: 300 mg/2 mL (150 mg/mL) in a single-dose vial
PDF page 95
Administer: IV INF route • Visually inspect for particulates and discoloration, product should be clear to opalescent, colorless to slightly yellow; discard if cloudy, discolored or visible particles are present • Do not shake • Withdraw and discard 2 mL of solu- tion from a 100 mL 0.9% NaCl injection, USP infusion bag • Withdraw 2 mL of solution from the vial and add to the infusion bag, mix the solu- tion by gentle inversion, do not shake • Discard any unused portion • Use immediately after preparation; if not used immediately, store diluted solution at room temperature (59°F-77°F, 15°C- 25°C) for ≤4 hr, or refrigerated (36°F- A 46°F, 2°C-8°C) for ≤24 hr; do not freeze, protect from light; if refrigerated, allow to come to room temperature before use • Give over 30 min; use an infusion line containing a sterile, low-protein-binding 0.2 or 0.22 micron in-line filter • Flush with 25 mL normal saline after completion, do not admix or administer through same line • Dispose of any equipment as per agency policy
PDF page 95
Assess: • Serious infections: Assess for ac- tive and chronic infections, avoid start- ing treatment in those with active infec- tions • Hypersensitivity: Serious hypersensi- tivity reactions, including anaphylaxis and angioedema have been reported • Malignancy: Assess history of past or present malignancies, assess risk factors for malignancy before use • Immunizations: Avoid use of live or live-attenuated vaccines in patients receiving, bring immunizations up to date before use
PDF page 95
Evaluate: • Therapeutic response: Decreasing ef- fects of SLE
PDF page 95
CLINICAL CONSIDERATIONS
PDF page 95
Patient and caregiver information: • Serious, chronic infections: Teach patient to report signs, symptoms of infec- tions (flulike symptoms, URI, bronchitis, or worsening of chronic infections) • Hypersensitivity: Inform patient to report any allergic reactions, including itching, rash, trouble breathing, immedi- ately to health care provider • Malignancy: Consider the individual benefit and risk in patients with known risk factors for malignancy before pre- scribing • Immunization: Bring immunizations up to date before use • Pregnancy/breastfeeding: Notify health care provider if pregnancy is planned or suspected or if breastfeeding
PDF pages 95, 96
PHARMACOKINETICS Onset, peak, duration unknown
PDF page 95
• Adult: IV INF 300 mg over 30 min q4wk
PDF page 95